Goldman Sachs
ATRA icon

Goldman Sachs’s Atara Biotherapeutics ATRA Stock Holding History

Goldman Sachs’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,770
Closed -$170K – 5647
2024
Q1 		$170K Sell
9,770
-13,518
-58% -$240K ﹤0.01% 5152
2023
Q4 		$299K Sell
23,288
-141,688
-86% -$3.3M ﹤0.01% 5008
2023
Q3 		$6.1M Sell
164,976
-17,504
-10% -$779K ﹤0.01% 2821
2023
Q2 		$7.34M Sell
182,480
-84,388
-32% -$4.77M ﹤0.01% 2750
2023
Q1 		$19.3M Buy
266,868
+17,123
+7% +$1.66M ﹤0.01% 1842
2022
Q4 		$20.5M Buy
249,745
+59,398
+31% +$6.19M 0.01% 1934
2022
Q3 		$18M Buy
190,347
+72,815
+62% +$8.18M ﹤0.01% 1964
2022
Q2 		$22.9M Sell
117,532
-27,992
-19% -$4.57M 0.01% 1787
2022
Q1 		$33.8M Buy
145,524
+42,943
+42% +$13.7M 0.01% 1635
2021
Q4 		$40.4M Sell
102,581
-12,390
-11% -$5.22M 0.01% 1523
2021
Q3 		$51.5M Buy
114,971
+11,063
+11% +$3.96M 0.01% 1262
2021
Q2 		$40.4M Buy
103,908
+19,039
+22% +$6.79M 0.01% 1443
2021
Q1 		$30.5M Sell
84,869
-20,990
-20% -$9.28M 0.01% 1580
2020
Q4 		$52M Sell
105,859
-20,750
-16% -$9.58M 0.01% 1098
2020
Q3 		$41M Sell
126,609
-14,460
-10% -$4.92M 0.01% 1148
2020
Q2 		$51.4M Buy
141,069
+115,763
+457% +$29.2M 0.02% 933
2020
Q1 		$5.38M Buy
25,306
+8,405
+50% +$2.67M ﹤0.01% 2580
2019
Q4 		$6.96M Buy
16,901
+823
+5% +$284K ﹤0.01% 2704
2019
Q3 		$5.68M Buy
16,078
+4,702
+41% +$1.75M ﹤0.01% 2758
2019
Q2 		$5.72M Buy
11,376
+1,002
+10% +$707K ﹤0.01% 2752
2019
Q1 		$10.3M Sell
10,374
-2,578
-20% -$2.4M ﹤0.01% 2384
2018
Q4 		$11.2M Sell
12,952
-3,463
-21% -$3.22M ﹤0.01% 2264
2018
Q3 		$17M Sell
16,415
-469
-3% -$459K ﹤0.01% 2047
2018
Q2 		$15.5M Buy
16,884
+9,956
+144% +$10.7M ﹤0.01% 2084
2018
Q1 		$6.75M Buy
6,928
+6,117
+754% +$5.57M ﹤0.01% 2661
2017
Q4 		$367K Buy
811
+13
+2% +$4.8K ﹤0.01% 5046
2017
Q3 		$330K Buy
798
+215
+37% +$81K ﹤0.01% 5394
2017
Q2 		$204K Sell
583
-7,466
-93% -$2.88M ﹤0.01% 5790
2017
Q1 		$4.13M Buy
8,049
+6,928
+618% +$2.87M ﹤0.01% 3100
2016
Q4 		$398K Sell
1,121
-143
-11% -$60.5K ﹤0.01% 5260
2016
Q3 		$676K Buy
1,264
+620
+96% +$337K ﹤0.01% 4759
2016
Q2 		$363K Buy
+644
New +$309K ﹤0.01% 5169
2015
Q4 		– Sell
-1,136
Closed -$893K – 7131
2015
Q3 		$893K Buy
+1,136
New +$1.39M ﹤0.01% 4584
2015
Q1 		– Sell
-2,100
Closed -$1.41M – 7065
2014
Q4 		$1.41M Buy
+2,100
New +$1.28M ﹤0.01% 4208

Other funds holding ATRA

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Centiva Capital New York $13.6B AUM 20% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Goldman Sachs's ATRA Position: Q2 2024 in Review

Goldman Sachs sold out of Atara Biotherapeutics (ATRA) in Q2 2024, closing a stake of 9,770 shares — an estimated $170K sold.

Goldman Sachs first reported a position in ATRA in Q4 2014 and held it in 34 quarters. The position peaked at $52M in Q4 2020. 48 funds tracked by Wall St. Rank hold ATRA as of Q2 2024.

  • Goldman Sachs reported no remaining Atara Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Goldman Sachs sold 9,770 Atara Biotherapeutics shares in Q2 2024, an estimated $170K.
  • Goldman Sachs first reported a position in Atara Biotherapeutics in Q4 2014 and held it in 34 quarters.
  • Goldman Sachs's Atara Biotherapeutics position peaked at $52M in Q4 2020.
  • 48 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2024.

Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.